{"disease":{"id":"systemic-sclerosis-associated-interstitial-lung-disease","name":"Systemic sclerosis associated interstitial lung disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nintedanib","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"ofev","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"vargatef","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07080125","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05878717","title":"A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03856853","title":"Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":144,"lead_sponsor_name":"Beijing Continent Pharmaceutical Co, Ltd.","has_results":false},{"nct_id":"NCT06105073","title":"\"Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis\"","phase":"","overall_status":"UNKNOWN","enrollment_count":67,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT06189495","title":"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02745145","title":"Abituzumab in SSc-ILD","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}